MANIPALHOS · NSE
Manipal Health Enterprises Limited
₹738.95
+2.41% (+₹17.4)
Prev. close
₹721.55
Volume
8,38,917
Delivery %
60.5%
As of
18 Sept 2026
Price history
Shivani Nyati · Swastika Investmart Ltd. · 05 Aug 2026
“Manipal Health Enterprises is trading at a premium valuation with limited margin of safety, as IPO proceeds are largely for debt repayment, not expansion. The company also has high revenue dependence on Karnataka. Existing allottees can hold, but fresh investors should await better entry levels or signs of further debt reduction. Maintain a stop-loss at ₹620 to protect listing gains.”
Entry ≈ ₹666.95 (first trade after call)Stop ₹620 (-7.0%)
Published mid-session at 14:49 IST. Tracking counts only prices printed after publication — the chart's dashed divider marks that moment; earlier prices never count toward entry or results.
Analyst sentiment
Analysts lean bullish
3 analyst stances · last 90 days · one per analyst
Trackable
3 · 2 bull / 1 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Initiated coverage on Manipal Health with a 'Buy' rating and a target price of ₹1,000, indicating a 25.32% upside from i…” | HSBC AnalysisHSBC | Manipal Health | PENDING | ||||
| “Manipal Health Enterprises is trading at a premium valuation with limited margin of safety, as IPO proceeds are largely …” | Shivani NyatiSwastika Investmart Ltd. | Manipal Health Enterprises | NOT GRADED | ||||
“Manipal Health Enterprises is trading at a premium valuation with limited margin of safety, as IPO proceeds are largely for debt repayment, not expansion. The company also has high revenue dependence on Karnataka. Existing allottees can hold, but fresh investors should await better entry levels or signs of further debt reduction. Maintain a stop-loss at ₹620 to protect listing gains.” Trade setupTrack opinion → This call couldn't be objectively graded against market data. | |||||||
| “Manipal Health Enterprises is set to become debt-free using IPO proceeds, a significant achievement in the healthcare se…” | Arun KejriwalKejriwal Research and Investment Services | Manipal Health Enterprises | NOT GRADED | ||||
Fundamentals
About Manipal Health Enterprises Limited
Manipal Health Enterprises Limited operates hospitals in India. The company offers services, such as multi-specialty tertiary and quaternary care through its network of hospitals. Its services include accident and emergency care, cancer care, cardiology, organ transplants, obstetrics and gynaecology, neurology, nephrology, orthopaedics, proctology, rheumatology, and urology. The company also offers medical services, including robotic spine surgery, bariatric surgery, head and neck surgery, liver transplantation, dialysis, laparoscopic surgery, organ transplant, orthopaedic robotic surgery, spine care, and clinics for conditions like epilepsy, chronic pain, and diabetes. In addition, it offers home care, a woman's and childcare centre, an insurance helpdesk, and international patient services, diagnostic services, pharmacy sales, home healthcare, teleconsultations, e-pharmacy, and digital health solutions. Further, it delivers outpatient treatment, diagnostics, and advanced clinical care through its hospital network, and collaborates with foundations and NGOs to offer healharmathcare services to underserved populations. The company was formerly known as Manipal Health Enterprises Private Limited and changed its name to Manipal Health Enterprises Limited in December 2025. The company was founded in 1991 and is headquartered in Bengaluru, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Mr. Dilip Jose Puthiyidathu
Headquarters
Bengaluru
Employees
24,240
Website
manipalhospitals.comExchange
View on NSE ↗Key stats
Market cap
₹97,364.22 Cr
P/E ratio (TTM)
146.6
EPS (TTM)
₹5.05
Shares float
14.05 Cr
Financial Performance
01 · Financials
FY24 growth needs FY23 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY24 | FY25 | FY26 |
|---|---|---|---|
| ₹6,079.39 Cr | ₹9,263.56 Cr | ₹10,935.62 Cr | |
| EBITDA | ₹1,546.86 Cr | ₹2,455.03 Cr | ₹2,834.87 Cr |
| ₹594.32 Cr | ₹512.96 Cr | ₹654.93 Cr | |
| Diluted EPS | ₹4.52 | ₹3.9 | — |
Diluted EPS has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | — | ₹10,818.83 Cr | ₹21,443.81 Cr | ₹24,864.50 Cr | |
| — | — | — | ₹5,130.25 Cr | ₹11,900.83 Cr | ₹12,863.06 Cr | |
| Stockholders' equity | — | — | — | ₹4,015.54 Cr | ₹5,820.04 Cr | ₹8,426.09 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY24 | FY25 | FY26 |
|---|---|---|---|
| ₹1,388.65 Cr | ₹1,569.83 Cr | ₹2,078.40 Cr | |
| Investing cash flow | ₹-870.50 Cr | ₹-2,658.34 Cr | ₹-7,036.74 Cr |
| ₹-250.21 Cr | ₹904.08 Cr | ₹4,954.44 Cr | |
| Capital expenditure | ₹-331.94 Cr | ₹-1,054.31 Cr | ₹-1,316.19 Cr |
| End cash position | ₹360.88 Cr | ₹291.28 Cr | ₹299.35 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Aug 26 |
|---|---|
| Promoter | 72.08% |
| Public | 27.92% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Aurobindo Pharma Limited | ₹97,238.87 Cr | ₹1,734 | 26.4 | 2.57 | 9.2% | 0.21 | +6.4% | +53.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.
Manipal Health redeems ₹5,310 crore debt using IPO proceeds
Manipal Health Enterprises redeemed non-convertible debentures worth ₹5,310 crore using proceeds from its Initial Public Offering. This debt repayment is expected to lower interest costs and provide financial flexibility for future expansion and investments. The company aims to strengthen its balance sheet and support growth plans.
Manipal Hospitals Expansion Targets 2,426 New Beds by 2030
Manipal Health Enterprises plans to add approximately 2,426 licensed beds by 2030, including 483 brownfield and 1,943 greenfield beds. This expansion, which includes a key greenfield project in Juhu, Mumbai, aims to strengthen its presence across India. The company is also evaluating acquisition opportunities and integrating digital systems to support its growth.